Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
McKesson
Baxter

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Lorcaserin hydrochloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for lorcaserin hydrochloride and what is the scope of patent protection?

Lorcaserin hydrochloride is the generic ingredient in two branded drugs marketed by Eisai Inc and is included in two NDAs. There are sixteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Lorcaserin hydrochloride has two hundred and six patent family members in forty-two countries.

There are five drug master file entries for lorcaserin hydrochloride. One supplier is listed for this compound.

Recent Clinical Trials for lorcaserin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southeastern Regional Medical CenterPhase 2
Kanion & Huawe Medicine Co.,LtdPhase 3
New York State Psychiatric InstituteEarly Phase 1

See all lorcaserin hydrochloride clinical trials

Recent Litigation for lorcaserin hydrochloride

Identify potential future generic entrants

District Court Litigation
Case NameDate
Arena Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-06
Arena Pharmaceuticals Inc. v. Lupin Ltd.2016-09-30

See all lorcaserin hydrochloride litigation

Pharmacology for lorcaserin hydrochloride
Synonyms for lorcaserin hydrochloride
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium chloride
(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride
(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(R)-1h-3-benzazepine,8-chloro-2,3,4,5-tetrahydro-1-methyl-,hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride salt
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride hemihydrate
0QJF08GDPE
1H-3-Benzazepine, 8-chloro-2,3,4,5-tetrahydro-1-methyl-, hydrochloride (1:1), (1R)-
846589-98-8
AB0080320
AC-8945
ACN-034447
ACT10402
AK142745
AKOS005145786
AN-7508
AOB87116
APD 356
APD-356
APD356
BC224447
BCP22731
BCP9000859
Belviq
Belviq (TN)
Belviq Xr
CHEBI:65350
CHEMBL2095211
CS-0752
D06613
DTXSID60233650
EX-A1697
FT-0696346
HY-15368
ITIHHRMYZPNGRC-QRPNPIFTSA-N
KS-0000006Z
KS-1439
Lorcaserin (Hydrochloride)
Lorcaserin HCl
Lorcaserin hydrochloride (USAN)
Lorcaserin hydrochloride [USAN]
Lorcaserin hydrochloride(APD-356)
Lorqess
MolPort-005-942-404
QC-9041
SCHEMBL173899
ST24035516
SW219573-1
UNII-0QJF08GDPE
W-5408
Paragraph IV (Patent) Challenges for LORCASERIN HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
BELVIQ TABLET;ORAL lorcaserin hydrochloride 022529 2019-06-27
BELVIQ XR TABLET, EXTENDED RELEASE;ORAL lorcaserin hydrochloride 208524 2016-12-13

US Patents and Regulatory Information for lorcaserin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
McKinsey
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.